Your browser doesn't support javascript.
loading
Risk of severe COVID in solid organ transplant recipient.
Barreiro, P; Candel, F J; Carretero, M M; San Román, J.
Affiliation
  • Barreiro P; Pablo Barreiro MD PhD, Regional Public Health Laboratory. Comunidad de Madrid. Infectious Diseases. Internal Medicine. Hospital General Universitario La Paz. Madrid, Spain. Department of Medical Specialties and Public Health. School of Medicine. Universidad Rey Juan Carlos, 28922 Madrid, Spain. pablo.barreiro@salud.madrid.org.
Rev Esp Quimioter ; 36 Suppl 1: 15-17, 2023 Nov.
Article in En | MEDLINE | ID: mdl-37997864
ABSTRACT
Despite the fact that COVID is today not a life-threat for the general population, recipients of solid organ transplantation should be viewed as a high risk group for severe COVID. Repetitive doses of SARS-CoV-2 vaccine still fail to protect SOT recipients from infection, disease or even death caused by COVID. A more frequent need for medical care may initially place these patients at greater chances of SARS-CoV-2 infection. Immunosuppression after engrafting and underlying medical conditions that led to the practice of SOT contribute to more risk of severe infection. Immunosuppression also blunts the intensity of humoral and cellular responses after vaccination, even when several booster doses have been administered. Still, vaccination is the best strategy to prevent a fatal outcome in case of SARS-CoV-2 infection, with a particular reduction in mortality. SOT recipients should be considered a high-risk population that need yearly SARS-CoV-2 vaccination.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organ Transplantation / COVID-19 Limits: Humans Language: En Journal: Rev Esp Quimioter Journal subject: TERAPIA POR MEDICAMENTOS Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organ Transplantation / COVID-19 Limits: Humans Language: En Journal: Rev Esp Quimioter Journal subject: TERAPIA POR MEDICAMENTOS Year: 2023 Document type: Article Affiliation country: